위장운동촉진제(Prokinetics)의 효능과 부작용
The Advantages and Disadvantages of Prokinetics
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Prokinetics are medications that enhance gastrointestinal contractility; they improve the symptoms of patients with delayed gastrointestinal motility. Prokinetics have conventionally been used to stimulate gastrointestinal propulsion and to treat symptoms correlated with motility problems, including gastroparesis and constipation. 5-Hydroxytryptamine receptor 4 (5-HT4) agonists, such as cisapride, very effectively increased human gastrointestinal tract motility. However, cisapride sometimes induced serious tachyarrhythmia; the drug was thus withdrawn from the market. Thereafter, many prokinetics have been developed to treat delayed gastrointestinal motility. However, some exhibit serious side-effects. Recently, a new, highly selective serotonin receptor agonist, prucalopride, has been introduced; there is as yet no evidence of serious cardiac side- effects. The drug has been approved by the Food and Drug Administration to treat chronic constipation. Thus, recently introduced, highly selective agents appear to show promise as treatments for gastrointestinal dysmotility; there seem to be no serious side-effects.
Abstract
Prokinetics are medications that enhance gastrointestinal contractility; they improve the symptoms of patients with delayed gastrointestinal motility. Prokinetics have conventionally been used to stimulate gastrointestinal propulsion and to treat symptoms correlated with motility problems, including gastroparesis and constipation. 5-Hydroxytryptamine receptor 4 (5-HT4) agonists, such as cisapride, very effectively increased human gastrointestinal tract motility. However, cisapride sometimes induced serious tachyarrhythmia; the drug was thus withdrawn from the market. Thereafter, many prokinetics have been developed to treat delayed gastrointestinal motility. However, some exhibit serious side-effects. Recently, a new, highly selective serotonin receptor agonist, prucalopride, has been introduced; there is as yet no evidence of serious cardiac side- effects. The drug has been approved by the Food and Drug Administration to treat chronic constipation. Thus, recently introduced, highly selective agents appear to show promise as treatments for gastrointestinal dysmotility; there seem to be no serious side-effects.
참고문헌 (52)
- Acosta A, "Prokinetics in gastroparesis", Gastroenterol Clin North Am, 44, pp.97~111 (2015)
- Gudsoorkar V, "Choosing a prokinetic for your patient beyond metoclopramide", Am J Gastroenterol, 115, pp.5~8 (2020)
- Jung Hwan Oh, "Clinical Practice Guidelines for Functional Dyspepsia in Korea", Journal of Neurogastroenterology and Motility (JNM), 26(1), pp.29~50 (2020), 대한소화기 기능성질환∙운동학회[DOI]
- Holtmann GJ, "Pathophysiology of irritable bowel syndrome", Lancet Gastroenterol Hepatol, 1, pp.133~146 (2016)
- Giudicessi JR, "Cardiovascular safety of prokinetic agents: a focus on drug-induced arrhythmias", Neurogastroenterol Motil, 30, pp.e13302~ (2018)
- Eamonn M M Quigley, "Prokinetics in the Management of Functional Gastrointestinal Disorders", Journal of Neurogastroenterology and Motility (JNM), 21(3), pp.330~336 (2015), 대한소화기 기능성질환∙운동학회[DOI]
- Karamanolis G, "Promotility medications--now and in the future", Dig Dis, 24, pp.297~307 (2006)
- Lee A, "Metoclopramide in the treatment of diabetic gastroparesis", Expert Rev Endocrinol Metab, 5, pp.653~662 (2010)
- Snape WJ Jr, "Metoclopramide to treat gastroparesis due to diabetes mellitus : a double-blind, controlled trial", Ann Intern Med, 96, pp.444~446 (1982)
- Cornett EM, "Medication-induced tardive dyskinesia : a review and update", Ochsner J, 17, pp.162~174 (2017)
- Rao AS, "Review article : metoclopramide and tardive dyskinesia", Aliment Pharmacol Ther, 31, pp.11~19 (2010)
- Yang YJ, "Prokinetics for the treatment of functional dyspepsia : Bayesian network meta-analysis", BMC Gastroenterol, 17, pp.83~ (2017)
- Singh H, "Efficacy and tolerability of levosulipride, domperidone and metoclopramide in patients with non-ulcer functional dyspepsia: a comparative analysis", J Clin Diagn Res., 9, pp.FC09~FC12 (2015)
- Weihrauch TR, "Evaluation of the effect of domperidone on human oesophageal and gastroduodenal motility by intraluminal manometry", Postgrad Med J., 55(Suppl 1), pp.7~10 (1979)
- Valenzuela JE, "Dopamine as a possible neurotransmitter in gastric relaxation", Gastroenterology, 71, pp.1019~1022 (1976)
- Silvers D, "Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. DOM-USA-5 Study Group", Clin Ther, 20, pp.438~453 (1998)
- Braun M, "Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine", Br J Clin Pharmacol, 67, pp.209~215 (2009)
- Leelakanok N, "Domperidone and risk of ventricular arrhythmia and cardiac death : a systematic review and meta-analysis", Clin Drug Investig, 36, pp.97~107 (2016)
- Doggrell SA, "Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine", Expert Opin Drug Saf, 13, pp.131~138 (2014)
- Chen HL, "Domperidone, cytochrome P450 3A4isoenzyme inhibitors and ventricular arrhythmia : a nationwide case-crossover study", Pharmacoepidemiol Drug Saf, 24, pp.841~848 (2015)
- Ford AC, "Efficacy of psychotropic drugs in functional dyspepsia : systematic review and meta-analysis", Gut, 66, pp.411~420 (2017)
- Shin HW, "Levosulpiride-induced movement disorders", Mov Disord, 24, pp.2249~2253 (2009)
- Talley NJ, "Itopride in functional dyspepsia : results of two phase III multicentre, randomised, double-blind, placebo-controlled trials", Gut, 57, pp.740~746 (2008)
- Holtmann G, "A placebo-controlled trial of itopride in functional dyspepsia", N Engl J Med, 354, pp.832~840 (2006)
- Huang X, "Itopride therapy for functional dyspepsia : a meta-analysis", World J Gastroenterol, 18, pp.7371~7377 (2012)
- Masuy I, "Review article : treatment options for functional dyspepsia", Aliment Pharmacol Ther, 49, pp.1134~1172 (2019)
- Abell TL, "Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility", Dig Dis Sci, 36, pp.616~620 (1991)
- Camilleri M, "Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction", Gastroenterology, 96, pp.704~712 (1989)
- Tonini M, "Review article : cardiac adverse effects of gastrointestinal prokinetics", Aliment Pharmacol Ther, 13, pp.1585~1591 (1999)
- Tack J, "Systematic review : cardiovascular safety profile of 5-HT(4)agonists developed for gastrointestinal disorders", Aliment Pharmacol Ther, 35, pp.745~767 (2012)
- Gershon MD, "The serotonin signaling system : from basic understanding to drug development for functional GI disorders", Gastroenterology, 132, pp.397~414 (2007)
- Vakil N, "Tegaserod treatment for dysmotility-like functional dyspepsia : results of two randomized, controlled trials", Am J Gastroenterol, 103, pp.1906~1919 (2008)
- Hongo M, "Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone : Japan Mosapride Mega-Study(JMMS)", J Gastroenterol Hepatol, 27, pp.62~68 (2012)
- Hallerbäck BI, "Dose finding study of mosapride in functional dyspepsia : a placebo-controlled, randomized study", Aliment Pharmacol Ther, 16, pp.959~967 (2002)
- Curran MP, "Mosapride in gastrointestinal disorders", Drugs, 68, pp.981~991 (2008)
- Hyuk Yoon, "Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia: A Randomized, Controlled Trial", Gut and Liver, 12(5), pp.516~522 (2018), 거트앤리버 소화기연관학회협의회
- Quigley EM, "Prucalopride : safety, efficacy and potential applications", Therap Adv Gastroenterol, 5, pp.23~30 (2012)
- Camilleri M, "A placebo-controlled trial of prucalopride for severe chronic constipation", N Engl J Med, 358, pp.2344~2354 (2008)
- Tack J, "Prucalopride(Resolor)in the treatment of severe chronic constipation in patients dissatisfied with laxatives", Gut, 58, pp.357~365 (2009)
- Quigley EM, "Clinical trial : the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study", Aliment Pharmacol Ther, 29, pp.315~328 (2009)
- Omer A, "An update on prucalopride in the treatment of chronic constipation", Therap Adv Gastroenterol, 10, pp.877~887 (2017)
- Gong J, "Randomised clinical trial : prucalopride, a colonic pro-motility agent, reduces the duration of post-operative ileus after elective gastrointestinal surgery", Aliment Pharmacol Ther, 43, pp.778~789 (2016)
- Emmanuel AV, "Randomised clinical trial : the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n = 1 study", Aliment Pharmacol Ther, 35, pp.48~55 (2012)
- Carbone F, "Prucalopride in gastroparesis : a randomized placebo-controlled crossover study", Am J Gastroenterol, 114, pp.1265~1274 (2019)
- Vijayvargiya P, "Use of prucalopride in adults with chronic idiopathic constipation", Expert Rev Clin Pharmacol, 12, pp.579~589 (2019)
- Arts J, "Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying", Gut, 54, pp.455~460 (2005)
- Richards RD, "The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin", Am J Gastroenterol, 88, pp.203~207 (1993)
- Sturm A, "Prokinetics in patients with gastroparesis : a systematic analysis", Digestion, 60, pp.422~427 (1999)
- Janssens J, "Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies", N Engl J Med, 322, pp.1028~1031 (1990)
- Camilleri M, "American College of Gastroenterology. Clinical guideline:management of gastroparesis", Am J Gastroenterol, 108, pp.18~38 (2013)
- Guo D, "The cardiotoxicity of macrolides : a systematic review", Pharmazie, 65, pp.631~640 (2010)
- Jean M Larson, "Advantages of Azithromycin Over Erythromycin in Improving the Gastric Emptying Half-Time in Adult Patients With Gastroparesis", Journal of Neurogastroenterology and Motility (JNM), 16(4), pp.407~413 (2010), 대한소화기 기능성질환∙운동학회